stdClass::__set_state(array( 'id' => '7745593', 'url' => 'FR/study_coordinator', 'image' => '', 'title' => 'Coordinateur de l\'étude clinique', 'tags' => array ( 0 => 'Coordinateur de l\'étude clinique', 1 => 'Pharmaceutical', 2 => 'Clinical trials', 3 => '', ), 'term' => 'Coordinateur de l\'étude clinique', 'source_id' => 1259718, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'lastedit' => '20150721084111', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Un membre du personnel qui, travaillant pour l\'investigateur principal, contacte les patients par rapport à l\'inscription à l\'étude, planifie les rendez-vous, maintient les registres nécessaires et gère le fonctionnement quotidien de l\'étude.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507294573052821504, 'nstext_full' => 'French (FR)', 's_attr' => stdClass::__set_state(array( 'Term' => 'study coordinator', 'Definition' => 'A staff person who works for the principal investigator to contact patients about enrolling in the study, schedule appointments, maintain required records and manage the day-to-day operation of the study.', 'Part of Speech' => 'noun', 'Usage Status' => 'New', 'Industry' => 'Pharmaceutical', 'Product Category' => 'Clinical trials', 'Creation User' => 'John Martin', 'Creation Date' => '2011/5/16', 'Source Lang' => '1180', )), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'study_coordinator', ))

stdClass::__set_state(array( 'id' => '6228059', 'url' => 'FR/single_blind_masking', 'image' => '', 'title' => 'Etude en simple aveugle', 'tags' => array ( 0 => 'Etude en simple aveugle', 1 => 'Medical devices', 2 => 'Pharmaceutical', 3 => 'Clinical trials', 4 => 'National Library of Medicine', 5 => '', ), 'term' => 'Etude en simple aveugle', 'source_id' => 4011054, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Medical devices', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'company' => array ( 0 => 'National Library of Medicine', ), 'lastedit' => '20150722105915', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Un type d\'étude en aveugle dans laquelle une partie impliquée dans l\'essai clinique, soit l\'investigateur soit le participant, ne sait pas à quels participants ont été assignées quelles interventions.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507393851745107970, 'nstext_full' => 'French (FR)', 's_attr' => stdClass::__set_state(array( 'Company' => 'National Library of Medicine', 'Definition' => 'A type of masking in which one party involved with the clinical trial, either the investigator or participant, does not know which participants have been assigned which interventions.', 'Industry' => 'Medical devices; Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Clinical trials', 'Creation User' => 'elighy', 'Creation Date' => '2012/10/13', 'Term' => 'single blind masking', 'Source Lang' => '1180', )), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'single_blind_masking', ))

stdClass::__set_state(array( 'id' => '6229774', 'url' => 'FR/clinical_trial_₁₁', 'image' => '', 'title' => 'Essai clinique', 'tags' => array ( 0 => 'Essai clinique', 1 => 'Medical devices', 2 => 'Pharmaceutical', 3 => 'Clinical trials', 4 => 'National Library of Medicine', 5 => '', ), 'term' => 'Essai clinique', 'source_id' => 4011597, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Medical devices', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'company' => array ( 0 => 'National Library of Medicine', ), 'lastedit' => '20150727104712', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Une étude clinique dans laquelle les participants sont assignés à recevoir une ou plusieurs interventions (ou pas d\'intervention) afin que les chercheurs puissent évaluer les effets des interventions sur les résultats biomédicaux ou liés à la santé. Les assignations sont déterminées par le protocole d\'étude. Les participants peuvent recevoir des interventions diagnostiques, thérapeutiques ou d\'autres types d\'interventions.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507846081755480064, 'nstext_full' => 'French (FR)', 's_attr' => stdClass::__set_state(array( 'Company' => 'National Library of Medicine', 'Definition' => 'A clinical study in which participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. The assignments are determined by the study protocol. Participants may receive diagnostic, therapeutic, or other types of interventions.', 'Industry' => 'Medical devices; Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Clinical trials', 'Synonym' => 'interventional_study', 'Creation User' => 'elighy', 'Creation Date' => '2012/10/13', 'Term' => 'clinical trial', 'Source Lang' => '1180', )), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'clinical_trial_₁₁', ))

stdClass::__set_state(array( 'id' => '6228620', 'url' => 'FR/primary_outcome_measure', 'image' => '', 'title' => 'Critère de jugement principal', 'tags' => array ( 0 => 'Critère de jugement principal', 1 => 'Medical devices', 2 => 'Pharmaceutical', 3 => 'Clinical trials', 4 => 'National Library of Medicine', 5 => '', ), 'term' => 'Critère de jugement principal', 'source_id' => 4011188, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Medical devices', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'company' => array ( 0 => 'National Library of Medicine', ), 'lastedit' => '20150727104701', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Le critère de jugement défini dans le protocole qui est le plus important pour évaluer l\'effet d\'une intervention. La plupart des études cliniques ont un critère de jugement principal, mais certaines peuvent en avoir plusieurs.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507846081752334336, 'nstext_full' => 'French (FR)', 's_attr' => stdClass::__set_state(array( 'Company' => 'National Library of Medicine', 'Definition' => 'The planned outcome measure in the protocol that is the most important for evaluating the effect of an intervention. Most clinical studies have one primary outcome measure, but some may have more than one.', 'Industry' => 'Medical devices; Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Clinical trials', 'Creation User' => 'elighy', 'Creation Date' => '2012/10/13', 'Term' => 'primary outcome measure', 'Source Lang' => '1180', )), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'primary_outcome_measure', ))

stdClass::__set_state(array( 'id' => '6877605', 'url' => 'FR/Angiotensin_II_Receptor_Blockers_(ARBs)', 'image' => '', 'title' => 'Antagonistes des récepteurs de l\'angiotensine II (ARA II)', 'tags' => array ( 0 => 'Antagonistes des récepteurs de l\'angiotensine II (ARA II)', 1 => 'Pharmaceutical', 2 => 'Drugs', 3 => '', ), 'term' => 'Antagonistes des récepteurs de l\'angiotensine II (ARA II)', 'source_id' => 1038764, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Drugs', ), 'lastedit' => '20150721084107', 'part_of_speech' => 'proper noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Médicaments qui bloquent l\'action de l\'angiotensine II en l\'empêchant de se lier à des récepteurs de l\'angiotensine II sur les vaisseaux sanguins.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507294573051772930, 'nstext_full' => 'French (FR)', 's_attr' => stdClass::__set_state(array( 'Term' => 'Angiotensin II Receptor Blockers (ARBs)', 'Definition' => 'Medications that block the action of angiotensin II by preventing angiotensin II from binding to angiotensin II receptors on blood vessels.', 'Part of Speech' => 'proper noun', 'Usage Status' => 'New', 'Industry' => 'Pharmaceutical', 'Product Category' => 'Drugs', 'Creation User' => 'CCTRADUCTION', 'Creation Date' => '2011/4/12', 'Source Lang' => '1180', )), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'Angiotensin_II_Receptor_Blockers_(ARBs)', ))

stdClass::__set_state(array( 'id' => '6229091', 'url' => 'FR/study_design', 'image' => '', 'title' => 'Plan d\'étude', 'tags' => array ( 0 => 'Plan d\'étude', 1 => 'Medical devices', 2 => 'Pharmaceutical', 3 => 'Clinical trials', 4 => 'National Library of Medicine', 5 => '', ), 'term' => 'Plan d\'étude', 'source_id' => 4011443, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Medical devices', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'company' => array ( 0 => 'National Library of Medicine', ), 'lastedit' => '20150727104709', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Les méthodes d\'investigation utilisées dans l\'étude clinique. Pour les études interventionnelles, celles-ci incluent un objectif principal, un modèle d\'intervention, en insu ou en aveugle, et une affectation.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507846081754431489, 'nstext_full' => 'French (FR)', 's_attr' => stdClass::__set_state(array( 'Company' => 'National Library of Medicine', 'Definition' => 'The investigative methods used in the clinical study. For interventional studies, these include primary purpose, intervention model , masking or blinding, and allocation.', 'Industry' => 'Medical devices; Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Clinical trials', 'Creation User' => 'elighy', 'Creation Date' => '2012/10/13', 'Term' => 'study design', 'Source Lang' => '1180', )), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'study_design', ))

stdClass::__set_state(array( 'id' => '3898053', 'url' => 'FR/variable_interval_₁', 'image' => '', 'title' => 'Intervalle variable', 'tags' => array ( 0 => 'Intervalle variable', 1 => 'Pharmaceutical', 2 => 'Pharmaceutical intermediates', 3 => '', ), 'term' => 'Intervalle variable', 'source_id' => 3744244, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Pharmaceutical intermediates', ), 'lastedit' => '20150722105901', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => '1) Un programme dans lequel une personne est renforcée par la première réponse après qu\'une période de temps variable soit passée depuis le renforcement précédent. Ce programme produit généralement un rythme de réponse uniforme. 2) Un programme de renforcement dans lequel une réponse est renforcée après qu\'une période de temps variable soit passée. Par exemple, dans un programme IV 30 secondes, l\'intervalle de temps varie entre chaque renforcement, mais l\'intervalle moyen de temps est de 30 secondes.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507393851728330752, 'nstext_full' => 'French (FR)', 's_attr' => stdClass::__set_state(array( 'Definition' => '1) A schedule in which a person is reinforced for the first response after a varying period of time has passed since the previous reinforcement. This schedule usually causes a person to respond at a uniform rate. 2) A schedule of reinforcement in which one response is reinforced after a variable amount of time has passed. For example, on a VI 30-second schedule, the time to each reinforcement changes but the average time is 30 seconds.', 'Domain' => 'Documentation', 'Industry' => 'Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Pharmaceutical intermediates', 'See Also' => 'interval schedules of reinforcement_₀', 'Usage Status' => 'New', 'Creation User' => 'lovinbnsingle', 'Creation Date' => '2012/9/5', 'Glossary' => 'MODULE_3_twgid1346807673617222', 'Term' => 'variable interval', 'Source Lang' => '1180', )), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'variable_interval_₁', ))

stdClass::__set_state(array( 'id' => '3951178', 'url' => 'FR/superbug', 'image' => 'Superbug.jpg;', 'title' => 'Superbactéries', 'tags' => array ( 0 => 'Superbactéries', 1 => 'Pharmaceutical', 2 => '', ), 'term' => 'Superbactéries', 'source_id' => 275134, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'lastedit' => '20150721084102', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Bactéries résistantes à presque tous les antibiotiques. Les gènes peuvent être transférés entre les bactéries par conjugaison, transduction ou transformation. Cela signifie que les gènes de résistance aux antibiotiques peuvent se lier à de nombreux types de germes courants et leur confèrent une importante résistance aux médicaments, en créant de superbactéries dangereuses. La dernière épidémie de superbactéries implique des patients qui ont voyagé en Inde où il y a une surpopulation et un usage excessif établi des antibiotiques. Beaucoup de gens en Inde manquent également d\'eau potable et ont des diarrhées répandues ; ce sont des conditions idéales pour la création de superbactéries.', 'usage_comment' => '', 'glossary' => '', 'width' => 450, 'height' => 362, '_version_' => 1507294573051772929, 'nstext_full' => 'French (FR)', 's_attr' => stdClass::__set_state(array( 'Term' => 'superbug', 'Definition' => 'Bacteria resistant to nearly all antibiotics. Genes can be transferred between bacteria by conjugation, transduction, or transformation. This means antibiotic resistance genes can hitch onto many types of common germs and confers broad drug resistance, creating dangerous superbugs. The latest outbreak of superbugs involve patients who have travel to India with an overpopulation and documented overuses antibiotics. Many people in India also lack clean water and have widespread diarrhea disease, which are ideal conditions for the creation of the superbug', 'Part of Speech' => 'noun', 'Usage Status' => 'New', 'Synonym' => 'super bacteria_₀; super bug_₀', 'Sample Image' => 'Superbug.jpg;', 'Industry' => 'Pharmaceutical', 'Domain' => 'Documentation; Marketing', 'Other Reference' => 'TIN', 'Creation User' => 'Bethsm', 'Creation Date' => '2010/9/14', 'Source Lang' => '1180', )), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'superbug', ))

stdClass::__set_state(array( 'id' => '6228624', 'url' => 'FR/Food_And_Drug_Administration_(FDA)', 'image' => '', 'title' => 'Food And Drug Administration (FDA)', 'tags' => array ( 0 => 'Food And Drug Administration (FDA)', 1 => 'Medical devices', 2 => 'Pharmaceutical', 3 => 'Clinical trials', 4 => 'National Library of Medicine', 5 => '', ), 'term' => 'Food And Drug Administration (FDA)', 'source_id' => 4011189, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Medical devices', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'company' => array ( 0 => 'National Library of Medicine', ), 'lastedit' => '20150727104702', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Une agence du Département de la Santé et des Services sociaux des États-Unis. La FDA est responsable de la protection de la santé publique. Elle se doit d\'assurer la sureté, l\'efficacité et la sécurité des médicaments humains et vétérinaires, des vaccins et autres produits biologiques, des dispositifs médicaux, de l\'approvisionnement alimentaire de la nation, des cosmétiques, des compléments alimentaires et des produits qui émettent des radiations.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507846081753382912, 'nstext_full' => 'French (FR)', 's_attr' => stdClass::__set_state(array( 'Company' => 'National Library of Medicine', 'Definition' => 'An agency within the U.S. Department of Health and Human Services. FDA is responsible for protecting the public health by making sure that human and veterinary drugs, vaccines and other biological products, medical devices, the nation\'s food supply, cosmetics, dietary supplements, and products that give off radiation are safe, effective, and secure.', 'Industry' => 'Medical devices; Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Clinical trials', 'Creation User' => 'elighy', 'Creation Date' => '2012/10/13', 'Term' => 'Food And Drug Administration (FDA)', 'Source Lang' => '1180', )), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'Food_And_Drug_Administration_(FDA)', ))

stdClass::__set_state(array( 'id' => '3898054', 'url' => 'FR/fixed-interval_₁', 'image' => '', 'title' => 'Intervalle fixe', 'tags' => array ( 0 => 'Intervalle fixe', 1 => 'Pharmaceutical', 2 => 'Pharmaceutical intermediates', 3 => '', ), 'term' => 'Intervalle fixe', 'source_id' => 3744252, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Pharmaceutical intermediates', ), 'lastedit' => '20150722105905', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Programme de renforcement. Un renforçateur dépend de la première réponse après un intervalle de temps fixe depuis la dernière opportunité pour un renforcement.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507393851728330753, 'nstext_full' => 'French (FR)', 's_attr' => stdClass::__set_state(array( 'Definition' => 'schedule of reinforcement. A reinforcer is contingent on the first response after a fixed interval of time since the last opportunity for reinforcement.', 'Domain' => 'Documentation', 'Industry' => 'Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Pharmaceutical intermediates', 'Usage Status' => 'New', 'Creation User' => 'lovinbnsingle', 'Creation Date' => '2012/9/5', 'Glossary' => 'MODULE_3_twgid1346807673617222', 'Term' => 'fixed-interval', 'Source Lang' => '1180', )), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'fixed-interval_₁', ))